Person: DURMUŞOĞLU, LÜTFİYE
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
DURMUŞOĞLU
First Name
LÜTFİYE
Name
7 results
Search Results
Now showing 1 - 7 of 7
Publication Open Access The effect of immunization with inactivated SARS-CoV-2 vaccine (CoronaVac) and/or SARS-CoV-2 infection on antibody levels, plasmablasts, long-lived-plasma-cells, and IFN-gamma release by natural killer cells(2022-04-01) HAKLAR, GONCAGÜL; KARAHASAN, AYŞEGÜL; DURMUŞOĞLU, LÜTFİYE; Bilgin H., Marku M., Yilmaz S. S., Karahasan Yagci A., Sili U., Can B., Can Sarinoglu R., Mulazimoglu Durmusoglu L., Haklar G., Sirikci O., et al.Objectives: We evaluated the antibody response, natural killer cell response and B cell phenotypes in healthcare workers (HCW) who are vaccinated with two doses of CoronaVac with or without documented SARS-CoV-2 infection and unvaccinated HCWs with SARS-CoV-2 infection. Methods: HCWs were divided into four groups: vaccine only (VO), vaccine after SARS-CoV-2 infection (VAI), SARS-CoV-2 infection only (IO), and SARS-CoV-2 infection after vaccine (IAV). Anti-SARS-CoV-2 spike protein (Anti-S) antibodies were measured by Elecsys Anti–SARS–CoV–2 S ELISA kit. Memory B cells (CD19+ CD27+ ), plasmablast B cells (CD19+ CD138+ ) and long-lived plasma cells (LLPC; CD138+ CD19- ) were measured by flow cytometry in 74 patients. Interferon gamma (IFN-c) release by natural killer (NK) cells were measured by NKVue Test (NKMAX, Republic of Korea) in 76 patients. RT-PCR was performed with Bio-speedy COVID-19 qPCR detection kit, Version 2 (Bioexen LTD, Istanbul, Turkey). Results: The Anti-S antibodies were detectable in all HCWs (n: 224). The median Anti-S titers (BAU/mL) was significantly higher in VAI (620 25–75% 373–1341) compared to VO (136, 25–75% 85–283) and IO (111, 25–75% 54–413, p < 0.01). VAI group had significantly lower percentage of plasmablasts (2.9; 0– 8.7) compared to VO (6.8; 3.5–12.0) and IO (9.9; 4.7–47.5, p < 0.01) (n:74). Percentage of LLPCs in groups VO, VAI and IO was similar. There was no difference of IFN-c levels between the study groups (n: 76). Conclusion: The antibody response was similar between uninfected vaccinated HCWs and unvaccinated HCWs who had natural infection. HCWs who had two doses of CoronaVac either before or after the natural SARS-CoV-2 infection elicited significantly higher antibody responses compared to uninfected vaccinated HCWs. The lower percentages of plasmablasts in the VAI group may indicate their migration to lymph nodes and initiation of the germinal center reaction phase. IFN-c response did not differ among the groups.Publication Open Access Development and Evaluation of Combined Effect Buccal Films for Treatment of Oral Candidiasis(2023-01-01) DURMUŞOĞLU, LÜTFİYE; Arslan D., AKBAL DAĞISTAN Ö., SAĞIRLI A. O., DURMUŞOĞLU L., CEVHER E., Yildiz-Pekoz A.© 2022, The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists.Buccal film formulations, including antifungal nystatin, anti-inflammatory agent hydrocortisone acetate, and local anesthetic lidocaine hydrochloride for pain relief, were developed. Bioadhesive films were fabricated with hydrophilic polymers, hydroxyethyl cellulose (HEC), and xanthan gum (XG) and dried in the incubator. Textural, swelling, and bioadhesive properties, physicochemical and in vitro release characteristics, and antifungal activities of bioadhesive films were evaluated. Bioadhesive films significantly extended nystatin release by prolonging retention time of the target area formulation while rapidly releasing hydrocortisone acetate and lidocaine HCl, reducing drug administration. The polymer type affected bioadhesion strength and erosion ratio, and XG formulations had more polymer suitability. Consequently, XT-O2 formulation that was prepared with xanthan gum and tween 80, was best for its highest antifungal film activity (20.00 ± 0.07 mm), released nystatin (44.296% ± 1.695), and lowest erosion matrix (36.719% ± 0.249). The selected formulation can be used for compatibility, stability and in vivo studies targeted oral candidiasis infections. Graphical Abstract: [Figure not available: see fulltext.]Publication Metadata only Enfeksiyon hastalıklarında ve tıpta yapay zekânın yeri ne olmalı? Genç bakış(Türkiye Klinikleri Yayınevi, 2022-11-01) DURMUŞOĞLU, LÜTFİYE; Durmuşoğlu L.Publication Metadata only Biosafety in anatomy laboratory(2023-01-01) DURMUŞOĞLU, LÜTFİYE; Güngördü B., Mülazimoğlu Durmuşoğlu L.Publication Open Access Pulmonary delivery offavipiravir in rats reaches high local concentrations without causing oxidative lung Injury or systemic side effects(2022-11-01) DURMUŞOĞLU, LÜTFİYE; YEGEN, BERRAK; Akbal-Dagistan O., Sevim M., Sen L. S. , Basarir N. S. , Culha M., Erturk A., Fael H., Kaptan E., Sancar S., DURMUŞOĞLU L., et al.Favipiravir displays a rapid viral clearance, a high recovery rate and broad therapeutic safety; however, its oral administration was associated with systemic side effects in susceptible patients. Considering that the pulmonary route could provide a high drug concentration, and a safer application with less absorption into systemic circulation, it was aimed to elucidate whether favipiravir delivered via soft-mist inhaler has any deleterious effects on lung, liver and kidney tissues of healthy rats. Wistar albino rats of both sexes (n = 72) were placed in restrainers, and were given either saline or favipiravir (1, 2.5, 5 or 10 mg/kg in 1 mL saline) by inhalation within 2 min for 5 consecutive days. On the 6th day, electrocardiographic recording was obtained, and cardiac blood and lung tissues were collected. Favipiravir did not alter cardiac rhythm, blood cell counts, serum levels of alanine transaminase, aspartate transaminase, blood urea nitrogen, creatinine, urea or uric acid, and did not cause any significant changes in the pulmonary malondialdehyde, myeloperoxidase activity or antioxidant glutathione levels. Our data revealed that pulmonary use of favipiravir via soft-mist inhaler enables a high local concentration compared to plasma without oxidative lung injury or cardiac or hepatorenal dysfunction.Publication Metadata only Antibiotic Usage Policies(2007-01-01) DURMUŞOĞLU, LÜTFİYE; DURMUŞOĞLU L.Publication Metadata only Tıpta ve enfeksiyon hastalıklarında yapay zekâ(Türkiye Klinikleri Yayınevi, 2022-11-01) ALTIKARDEŞ, ZEHRA AYSUN; DURMUŞOĞLU, LÜTFİYE; Durmuşoğlu L. (Editör), Altıkardeş Z. A. (Editör)